SYK Stryker

Stryker Corporation is a major medical device company specializing in orthopedic implants, surgical instruments, neurotechnology, and medical robotics. Sector: Healthcare.

Stryker (SYK) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

On a capital return basis, ROIC is 10.68%, WACC is 8.91%, and the economic spread is 1.77%. On balance, the economic spread is positive but compressed — adequate for value preservation, less convincing for aggressive compounding. Supporting metrics show ROE at 15.12% and ROA at 7.49%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that is value-creative but with less room for execution slippage.

On valuation, the company registers trailing P/E of 39.47, forward P/E of 22.14, PEG of 1.89. Forward P/E is considerably lower than trailing, which indicates earnings estimates are pointing higher — a dynamic that makes current prices look more reasonable on a prospective basis. The PEG reading here implies the market is pricing growth at roughly fair value — a setup where the investment case depends more on execution than on multiple expansion. A current ratio of 1.89 suggests the the company have sufficient short-term liquidity without excess. Taken together, the multiple and liquidity picture suggests a company that is priced for a constructive outcome — but where execution against earnings estimates will be the key determinant of whether that price is justified.

Stripping to unit economics, gross margin sits at 64.50%, operating margin at 21.53%, and free cash flow margin at 17.05%. Gross margins are exceptional, reflecting strong pricing power and a defensible cost structure. The operating margin reading is constructive, suggesting management teams are managing overhead costs effectively. At this FCF margin level, the company demonstrate good cash generation relative to the revenue base. Read in combination, these margins suggest a business model that protects profitability across multiple cost layers.

Revenue trends and analyst expectations together suggest: TTM revenue growth of 11.42% indicating steady top-line growth at the company level, while the estimated 12-month price change of 30.91%, where consensus targets imply substantial appreciation potential over the next 12 months. At 78.3%, the projected 12-month EPS growth rate is strong enough to be a primary driver of the forward investment case rather than a peripheral supporting detail. There is always distance between what is reported and what is priced; the question of whether that distance is closing or widening is what makes the setup interesting. In either direction, the fundamental driver of returns will be whether the company can sustain the trajectory that is already being priced. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The aggregate picture across capital efficiency, valuation, growth, and cash generation builds a compelling case.

This assessment is based solely on the quantitative metrics presented above and does not constitute financial advice. Investors should consider their own risk tolerance and conduct independent research before making investment decisions.